Search Result

Results for "

monoclonal-antibodies

" in MedChemExpress (MCE) Product Catalog:

By Targets:	ADC Antibody (49) Antibody-Drug Conjugates (ADCs) (31) Antibody-Oligonucleotide Conjugates (AOCs) (1) ADAMTS (1) ADC Linker (1) ADC Payload (2) Adenosine Receptor (1) Adenylate Cyclase (2) Adhesion G Protein-coupled Receptors (AGPCRs) (1) Akt (11) ALCAM/CD166 (2) Amino Acid Derivatives (1) Amylin Receptor (1) Amyloid-β (16) Anaplastic lymphoma kinase (ALK) (3) Angiotensin-converting Enzyme (ACE) (2) ANGPTL (1) Antibiotic (3) Antifolate (4) Apolipoprotein (1) Apoptosis (42) Atg8/LC3 (1) ATGL (1) Bacterial (11) Bcl-2 Family (1) Beclin1 (1) Biochemical Assay Reagents (11) c-Fms (10) c-Kit (5) c-Met/HGFR (11) c-Myc (1) C-type Lectin-like Receptors (CTLRs) (10) Cadherin (4) Carbonic Anhydrase (1) Caspase (4) CCR (14) CD1 (2) CD19 (12) CD2 (2) CD20 (19) CD22 (7) CD276/B7-H3 (6) CD28 (11) CD3 (19) CD38 (10) CD44 (1) CD47 (10) CD6 (1) CD73 (11) CD74 (2) CDK (1) CGRP Receptor (4) Cholecystokinin Receptor (1) Claudin (6) CMV (1) Collagen (1) Complement System (16) Connective Peptide (1) CTLA-4 (16) CX3CR1 (2) CXCR (12) Dan family (2) Dipeptidyl Peptidase (2) Discoidin Domain Receptor (1) DNA/RNA Synthesis (3) Drug-Linker Conjugates for ADC (6) E-Selectin (1) E1/E2/E3 Enzyme (1) EAAT (1) EGFR (65) Endothelin Receptor (1) Ephrin Receptor (1) ERK (4) Estrogen Receptor/ERR (2) Factor VIII (2) Factor Xa (5) Factor XI (4) FAP (2) Fc Receptor (FcR) (13) Ferroptosis (2) FGFR (8) Filovirus (6) FLT3 (3) Fungal (2) Galectin (3) Gap Junction Protein (1) GCGR (2) GLP Receptor (1) Glucosylceramide Synthase (GCS) (1) Glutaminase (1) Glutathione Peroxidase (1) Glycoprotein VI (3) Guanylate Cyclase (1) HBV (4) HCV (1) HDAC (1) HIF/HIF Prolyl-Hydroxylase (1) Histamine Receptor (1) HIV (13) HMG Family (2) HSP (1) HSV (1) IFNAR (18) IGF-1R (13) iGluR (1) Indoleamine 2,3-Dioxygenase (IDO) (1) Influenza Virus (10) Insulin Receptor (5) Integrin (33) Interleukin Related (180) JNK (2) Kallikrein (1) Keap1-Nrf2 (2) L-Selectin (2) LAG-3 (19) LDLR (1) LOX-1 (1) LPL Receptor (3) Macrophage migration inhibitory factor (MIF) (1) MDM-2/p53 (2) Melanocortin Receptor (1) Mesothelin (1) MHC (11) Microtubule/Tubulin (13) MMP (7) Monoamine Oxidase (1) mTOR (2) Mucin (13) MyD88 (1) Myosin (1) nAChR (2) NAMPT (2) Neurokinin Receptor (2) Neurotensin Receptor (1) NF-κB (18) NO Synthase (2) NOD-like Receptor (NLR) (3) Notch (10) NTPDase (2) Orexin Receptor (OX Receptor) (13) Orphan GPCR (2) Osteopontin (1) P-glycoprotein (1) P-selectin (2) p38 MAPK (3) PACAP Receptor (1) PAI-1 (2) Parasite (3) PARP (1) PCSK9 (8) PD-1/PD-L1 (73) PDGFR (2) PERK (3) Phosphatase (2) PI3K (2) PSMA (6) RABV (5) Radionuclide-Drug Conjugates (RDCs) (10) RANKL/RANK (3) Ras (2) Reactive Oxygen Species (ROS) (4) Repulsive guidance molecule (1) RET (1) ROR (1) RSV (14) SARS-CoV (33) Ser/Thr Protease (4) Sialyltransferase (1) SLC39 (Zinc Transporter) (1) Small Interfering RNA (siRNA) (1) Sodium Phosphate Cotransporter (1) Src (1) STAT (9) STING (1) Survivin (1) TAM Receptor (1) Tau Protein (11) TGF-beta/Smad (14) TGF-β Receptor (10) Thrombin (2) Thyroid Hormone Receptor (1) Tie (6) Tim3 (5) Tissue Factor Pathway Inhibitor (TFPI) (2) TNF Receptor (105) Toll-like Receptor (TLR) (9) Topoisomerase (5) Transferrin Receptor (3) Transmembrane Glycoprotein (91) Transthyretin (TTR) (3) TREM receptor (3) Trk Receptor (10) TROP2 (4) TSH Receptor (2) Tyrosinase (2) VAP-1 (2) VEGFR (31) Virus Protease (2) VISTA (4) Wnt (10) α-synuclein (2) β-catenin (1)
By Research Areas:	Cancer (738) Cardiovascular Disease (51) Endocrinology (14) Infection (120) Inflammation/Immunology (565) Metabolic Disease (50) Neurological Disease (72)
Click Chemistry:	DBCO (1)

1264

Inhibitors & Agonists

Screening Libraries

Biochemical Assay Reagents

Peptides

1322

Inhibitory Antibodies

Natural
Products

Click Chemistry

Targets Recommended: ADC Antibody Antibody-Drug Conjugates (ADCs) Antibody-Oligonucleotide Conjugates (AOCs)

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-P99604

Cilgavimab AZD-1061; COV2-2130	SARS-CoV	Infection
Cilgavimab (AZD-1061; COV2-2130) is a human SARS-CoV-2-neutralizing monoclonal antibody, can compose monoclonal-antibody combination AZD7442 with Tixagevimab (HY-P99556). Cilgavimab shows protective action on mouse models of SARS-CoV-2 infection .

HY-P99232

Indusatumab 5F9 monoclonal antibody	Guanylate Cyclase	Cancer
Indusatumab (5F9 Monoclonal antibody) is an anti-human GUCY2C (Guanylate cyclase 2C) monoclonal antibody .

HY-P99825

Relfovetmab	TNF Receptor	Neurological Disease Inflammation/Immunology
Relfovetmab is an anti-NGF monoclonal antibody (mAb) .

HY-P990780

Zeleciment	Transferrin Receptor Antibody-Oligonucleotide Conjugates (AOCs)	Inflammation/Immunology
Zeleciment is an anti-TFRC IgG1κ monoclonal antibody .

HY-P99784

Porgaviximab	Filovirus	Infection
Porgaviximab is a monoclonal antibody that can be used Ebola infection research .

HY-P990715

Ozekibart INBRX-109	TNF Receptor	Inflammation/Immunology
Ozekibart is an anti-TNFRSF10B monoclonal antibody .

HY-P990703

Porustobart HBM-4003	CTLA-4	Inflammation/Immunology
Porustobart is an anti-CTLA4 monoclonal antibody .

HY-P990030

Ralzapastotug AB-308	Transmembrane Glycoprotein	Infection Inflammation/Immunology
Ralzapastotug (AB-308) is an anti-TIGIT (T cell immunoreceptor with Ig and ITIM domains) IgG1 monoclonal antibody. Ralzapastotug is a monoclonal antibody targeting amino acids 106-126 of the cellular prion protein PrP ^C .

HY-P99948

Etevritamab AMG-596	EGFR	Inflammation/Immunology
Etevritamab is an anti-CD3E/EGFR monoclonal antibody .

HY-P991181

VTX-1218	Transmembrane Glycoprotein	Cancer
VTX-1218 is a humanized IgG1 monoclonal antibody targeting VSIG4.

HY-P9943

Igovomab	Transmembrane Glycoprotein	Cancer
Igovomab is a monoclonal antibody for imaging. Igovomab can be used for ovarian cancer research .

HY-P990740

Fanastomig EMB-02; EMB-02	PD-1/PD-L1 LAG-3	Inflammation/Immunology
Fanastomig is an anti-PDCD1/LAG3 monoclonal antibody .

HY-P990742

Givastomig	TNF Receptor	Inflammation/Immunology
Givastomig is an anti-TNFRSF9/CLDN18 monoclonal antibody .

HY-P99526

Vapaliximab 2D10	VAP-1	Inflammation/Immunology
Vapaliximab (2D10) is a monoclonal antibody against human VAP-1 .

HY-P990689

Zifibancimig RO-7250284	VEGFR	Inflammation/Immunology
Zifibancimig is an anti-VEGFA/ANGPT2 IgG1κ monoclonal antibody .

HY-P99251

Lodelcizumab	PCSK9	Others
Lodelcizumab is a *monoclonal antibody* targeting PCSK9. Lodelcizumab can be used for the research of hypercholesterolemia .

HY-P990778

Xirestomig	TNF Receptor PD-1/PD-L1	Inflammation/Immunology
Xirestomig is an anti-TNFRSF9/CD274 monoclonal antibody .

HY-P990738

Enristomig ES-101; INBRX-105	TNF Receptor PD-1/PD-L1	Inflammation/Immunology
Enristomig is an anti-TNFRSF9/CD274 monoclonal antibody .

HY-P990722

Danvilostomig	PD-1/PD-L1	Inflammation/Immunology
Danvilostomig is an anti-CTLA4/PDCD1 monoclonal antibody .

HY-P99709

Lodapolimab LY3300054	PD-1/PD-L1	Cancer
Lodapolimab (LY3300054) is an IgGλ anti-PD-1 monoclonal antibody .

HY-P99624

Foravirumab CR4098	RABV	Infection
Foravirumab (CR4098) is a monoclonal antibody against rabies virus glycoprotein antigenic site III .

HY-P991560

TQB-2928	CD47	Cancer
TQB-2928 is a monoclonal antibody against CD47, which can be used in the study of cancer.

HY-P99723

Manelimab BCD-135	PD-1/PD-L1	Cancer
Manelimab is a monoclonal antibody that inhibits programmed death-ligand 1 (PD-L1) .

HY-P991190

Rilogrotug AV-380	TGF-beta/Smad	Cancer
Rilogrotug (AV-380) is a humanized IgG1 monoclonal antibody targeting GDF15 .

HY-P99635

Gatralimab GZ-402668	NF-κB	Cancer
Gatralimab (GZ-402668) is an IgG1 anti-CD52 monoclonal antibody .

HY-P991626

VGX200	VEGFR	Others
VGX200 is a monoclonal antibody against vascular endothelial growth factor D (VEGFD) .

HY-P99916

Emirodatamab AMG-427	FLT3	Inflammation/Immunology
Emirodatamab is an anti-CD3E/FLT3 monoclonal antibody .

HY-P99108

Penpulimab	PD-1/PD-L1	Inflammation/Immunology Cancer
Penpulimab is an IgG1 backbone anti-PD-1 monoclonal antibody with antitumor activities .

HY-P99447

Atidortoxumab	Bacterial	Infection
Atidortoxumab is a human IgG1κ monoclonal antibody that targets Staph aureus alpha toxin .

HY-P99577

Taplitumomab	CD19	Cancer
Taplitumomab is an anti-CD19 monoclonal antibody. Taplitumomab paptox can be used in cancer research.

HY-P990688

Xaluritamig AMG-509	CD3	Inflammation/Immunology
Xaluritamig is an anti-CD3E/STEAP1 monoclonal antibody .

HY-P99451

Avizakimab BOS161721	Interleukin Related	Inflammation/Immunology
Avizakimab (BOS161721) is a humanized IgG1 monoclonal antibody that targets interleukin-21 .

HY-P990759

Rezetamig	CD22	Inflammation/Immunology
Rezetamig is an anti-CD3E/CD22 monoclonal antibody .

HY-P99535

Upanovimab SCTA01	SARS-CoV	Cancer
Upanovimab (SCTA01) is a monoclonal antibody that targets the SARS-CoV-2 S protein .

HY-P9906

Bevacizumab 35+ Cited Publications Anti-Human VEGF, Humanized Antibody	VEGFR	Cancer
Bevacizumab, a humanized IgG1 monoclonal antibody, specifically binds to all VEGF-A isoforms with high affinity.

HY-P99663

Inezetamab	TNF Receptor	Cancer
Inezetamab is a bispecific anti-CD40 and anti-MSLN IgG1 monoclonal antibody .

HY-P99628

Futuximab	EGFR	Cancer
Futuximab is a chimeric monoclonal antibody targeting non-overlapping epitopes on EGFR. Futuximab has antineoplastic activity .

HY-P990727

Alextatug	DNA/RNA Synthesis	Inflammation/Immunology
Alextatug is an anti-PABPC1 human IgG1 λ7 monoclonal antibody .

HY-P99808

Pulocimab	VEGFR	Cancer
Pulocimab is an anti-VEGFR2 monoclonal antibody (mAb). Pulocimab can be used for the research of cancers .

HY-P9913

Rituximab 5+ Cited Publications Anti-Human CD20 type I, Chimeric Antibody	Radionuclide-Drug Conjugates (RDCs) CD20	Inflammation/Immunology Cancer
Rituximab is an anti-CD20 chimeric monoclonal antibody used for research of certain autoimmune diseases and cancer.

HY-P3893

PSTAIR	CDK	Metabolic Disease
PSTAIR is a monoclonal antibody that recognizes the PSTAIR sequence in Cdc28, PSTAIR can be used as loading control .

HY-P991379

MG1113A	Tissue Factor Pathway Inhibitor (TFPI)	Others
MG1113A is a human monoclonal antibody (mAb) targeting TFPI. MG1113A can be used in Haemophilia research.

HY-P991189

AMG-305	Mesothelin	Cancer
AMG-305 is a humanized IgG1 monoclonal antibody targeting CDH3/MSLN ^.

HY-P990020

Eglatoprutug	c-Kit	Others
Eglatoprutug is an humanized immunoglobulin G1-kappa, anti-c-Kit monoclonal antibody .

HY-P990735

Donzakimig	Interleukin Related	Inflammation/Immunology
Donzakimig is an anti-IL13/IL22/ALB monoclonal antibody .

HY-P990699

Riltovetbart ZTS-00008183	Interleukin Related	Inflammation/Immunology
Riltovetbart is a canine-derived IgG2 κ monoclonal antibody raised against Canlupfam IL13 .

HY-P991083

MAS825	Interleukin Related	Inflammation/Immunology
MAS825 is a bispecific IL-1β and IL-18 monoclonal antibody that reduces inflammasome-mediated inflammation. MAS825 combines the anti-IL-1β and anti-IL-18 monoclonal antibodies (mAbs) inhibition domains in a single bispecific high-affinity cytokine capture molecule .

HY-P991625

VX70	VEGFR	Cancer
VX70 is a humanized monoclonal antibody inhibitor targeting VEGF-A. VX70 can be used for cancers research .

HY-P99943

Erfonrilimab KN-046	PD-1/PD-L1 CTLA-4	Inflammation/Immunology
Erfonrilimab (KN-046) is an anti-PDL1/CTLA-4 monoclonal antibody .

HY-P99558

Timigutuzumab GEXMab73; GT-MAb7.3-GEX; TrastuzuMab-GEX	EGFR	Cancer
Timigutuzumab (GEXMab73) is a humanized monoclonal antibody that targets ErbB2. Timigutuzumab can be used for the research of cancer .

Cat. No.	Product Name

HY-L080

Targeted Therapy Drug Library

106 compounds

Targeted cancer therapies are drugs or other substances that block the growth and spread of cancer by interfering with specific molecular targets that are involved in the growth, progression, and spread of cancer.

There are several different types of targeted therapy. The most common types are small-molecule drugs and monoclonal antibodies. Small-molecule drugs are small enough to enter cells easily, so they are used for targets that are inside cells, while monoclonal antibodies are usually used for targets that are located outside the cells. Because of high specificity, low side effect and potent anticancer activity, targeted therapy has become the mainstream of new anti-tumor drugs. Various targeted therapies have been approved by FDA and used in the treatment of diseases.

MCE carefully collects a unique of 106 targeted therapy drugs used in cancer treatment. MCE Targeted therapy drug library is a useful tool for the research of targeted therapy.

HY-L023

Toxins for Antibody-Drug Conjugate Research Library

118 compounds

Antibody-Drug Conjugates (ADCs), a new class of treatment for cancer, are composed with a monoclonal antibody, a linker and a cytotoxic agent also referred to as a payload. To date, several ADCs have received market approval and more than 60 ADCs are currently in clinical trials. ADCs are one of the fastest growing classes of oncology drugs worldwide.

The payload or cytotoxic agent is the most important unit in the ADC. ADC has the capability to kill cancer cell depending on the potency of the payload. MCE provides 118 highly potent cytotoxins that contain auristatin derivatives, maytansinoids, calicheamicin, duocarmycin, pyrrolobenzodiazepines (PBDs), etc.

HY-L031

Small Molecule Immuno-Oncology Compound Library

682 compounds

Immuno-Oncology is a type of immunotherapy that has the specific purpose of treating cancer. It works by stimulating our immune system to fight back. Normally, our immune system is able to destroy cancer cells in our body, however sometimes cancer cells can adapt and mutate, effectively hiding from our immune system. This is when tumors can develop and become a threat to our health. Immuno-oncology involves mobilizing lymphocytes to recognize and eliminate cancer cells using the body’s immune system. There are several immuno-oncology treatments available, including Immune cell therapy (CAR-T), monoclonal antibodies (mABs) and checkpoint inhibitors, cytokines and cancer vaccines.

MCE Small Molecule Immuno-Oncology Compound Library offers 682 bioactive tumor immunology compounds that target some important checkpoints such as PD1/PD-L1, CXCR, Sting, IDO, TLR, etc. This library is a useful tool for Immuno-oncology research.

Cat. No.	Product Name	Type

HY-158067

Deferoxamine-DBCO

DFO-DBCO

Chelators

Deferoxamine-DBCO is a bifunctional chelating agent. Deferoxamine-DBCO efficiently chelates with radioactive metals (such as ⁸⁹Zr) through the DFO structure to achieve radiolabeling. Deferoxamine-DBCO undergoes a metal-free Huisgen cycloaddition reaction with azide-containing biomolecules (such as siRNA, monoclonal antibodies) under bioorthogonal conditions through the DBCO structure to achieve targeted coupling. Deferoxamine-DBCO has efficient metal chelating ability and specific bioorthogonal reaction activity. Deferoxamine-DBCO can be used for targeted radioactive imaging studies of tumors .

HY-D1056A3

Lipopolysaccharides, from E. coli O26:B6

LPS, from Escherichia coli (O26:B6)

Carbohydrates

Lipopolysaccharides, from E. coli (Escherichia coli) O26:B6 are lipopolysaccharide endotoxins and TLR-4 activators derived from E. coli, classified as S-type LPS, which can activate pathogen-associated molecular patterns (PAMP) of the immune system and induce cellular secretion of migrasomes. Lipopolysaccharides, from E. coli O26:B6 exhibit a typical three-part structure: O-antigen (O-antigen), core oligosaccharide (core oligosaccharide), and lipid A (Lipid A), and can be recognized by the core-specific monoclonal antibody MAb J8-4C10. Lipopolysaccharides, from E. coli O26:B6 can promote an increase in pro-inflammatory cytokines in plasma, thereby triggering hypothalamic-pituitary-adrenal (HPA) activation and leading to adrenal oxidative damage. The pathogenic effects of Lipopolysaccharides, from E. coli O26:B6 can be blocked by PD149163 (HY-123434) .
It is recommended to prepare a stock solution of ≥2 mg/mL and ensure that it is fully mixed and dissolved. Due to the adsorption characteristics of LPS, low adsorption centrifuge tubes should be used for aliquoting and storage.

Cat. No.	Product Name	Target	Research Area

HY-P3893

PSTAIR	CDK	Metabolic Disease
PSTAIR is a monoclonal antibody that recognizes the PSTAIR sequence in Cdc28, PSTAIR can be used as loading control .

HY-P10544

*Humanized anti-tac (HAT) binding peptide*	Interleukin Related	Others
Humanized anti-tac (HAT) binding peptide is a peptide that can specifically bind to the Fc region of HAT. HAT is a humanized monoclonal antibody against the low affinity p55 subunit of the interleukin IL-2 receptor. Humanized anti-tac (HAT) binding peptide can be used to develop affinity chromatography media to purify specific monoclonal antibodies .

HY-P4025

ELDKWA	HIV	Others
ELDKWA is the highly conserved amino acids on the ecto-domain of gp41. ELDKWA acts as the epitope of a neutralizing monoclonal antibody 2F5 (mAb 2F5) directed against human immunodeficiency virus type 1 .

HY-P4810

Polyphemusin II-Derived Peptide T140	CXCR	Infection
Polyphemusin II-Derived Peptide (T140), a CXCR4 inhibitor, shows high inhibitory activity against HIV-1 entry and the inhibitory effect on the binding of an anti-CXCR4 monoclonal antibody (12G5) to CXCR4 .

HY-P11031

CotH3 peptide	Fungal	Infection
CotH3 peptide is a functional peptide unique to Mucorales that binds to the host GRP78 receptor and allows them to invade endothelial cells. CotH3 peptide–targeted monoclonal antibodies protect immunosuppressed mice from mucormycosis caused by R. delemar and other Mucorales. CotH3 peptide also synergizes with antifungal drugs to protect mice with diabetic ketoacidosis (DKA) from R. delemar infection .

HY-P5413

[Lys3]-Bombesin	Cholecystokinin Receptor	Others
[Lys3]-Bombesin is a biological active peptide. (PET (Positron Emission Tomography) imaging of [Lys3]-bombesin is able to detect gastrin-releasing peptide receptor (GRPR) positive prostate cancer. An immunoconjugate of [Lys3]-bombesin and corresponding monoclonal antibody can specifically induce (CD64)-dependent monocyte and neutrophil-mediated lysis of small cell carcinoma.)

HY-P11084

WT1 126-134 peptide	MHC	Inflammation/Immunology Cancer
WT1 126-134 peptide is a Wilms' tumor oncogene protein (WT1) peptide (RMFPNAPYL). WT1 126-134 peptide is presented by HLA-A0201 and induces cytotoxic CD8 T cells capable of killing WT1+ positive tumor cells. WT1 126-134 can form stable complexes with the H-2Db (mouse) or HLA-A0201 (human) molecules. WT1 126-134 peptide/HLA-A0201 complex has an extremely high affinity (K_d = 0.2 nM) with the humanized monoclonal antibody (IgG1). WT1 126-134 peptide can be used as a vaccine for T cells or as a target for antibodies .

Cat. No.	Product Name		Classification